Hospital length of stay among children with and without congenital anomalies across 11 European regions-A population-based data linkage study.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2022
Historique:
received: 08 03 2022
accepted: 29 05 2022
entrez: 22 7 2022
pubmed: 23 7 2022
medline: 27 7 2022
Statut: epublish

Résumé

Congenital anomalies are a leading cause of childhood morbidity, but little is known about the long-term outcomes. To quantify the burden of disease in childhood for children with congenital anomalies by assessing the risk of hospitalisation, the number of days spent in hospital and proportion of children with extended stays (≥10 days). European population-based record-linkage study in 11 regions in eight countries including children with congenital anomalies (EUROCAT children) and without congenital anomalies (reference children) living in the same regions. The children were born between 1995 and 2014 and were followed to their tenth birthday or 31/12/2015. European meta-analyses of the outcome measures were performed by two age groups, <1 year and 1-4 years. 99,416 EUROCAT children and 2,021,772 reference children were linked to hospital databases. Among EUROCAT children, 85% (95%-CI: 79-90%) were hospitalised in the first year and 56% (95%-CI: 51-61%) at ages 1-4 years, compared to 31% (95%-CI: 26-37%) and 25% (95%-CI: 19-31%) of the reference children. Median length of stay was 2-3 times longer for EUROCAT children in both age groups. The percentages of children with extended stays (≥10 days) in the first year were 24% (95%-CI: 20-29%) for EUROCAT children and 1% (95%-CI: 1-2%) for reference children. The median length of stay varied greatly between congenital anomaly subgroups, with children with gastrointestinal anomalies and congenital heart defects having the longest stays. Children with congenital anomalies were more frequently hospitalised and median length of stay was longer. The outlook improves after the first year. Parents of children with congenital anomalies should be informed about the increased hospitalisations required for their child's care and the impact on family life and siblings, and they should be adequately supported.

Sections du résumé

BACKGROUND
Congenital anomalies are a leading cause of childhood morbidity, but little is known about the long-term outcomes.
OBJECTIVE
To quantify the burden of disease in childhood for children with congenital anomalies by assessing the risk of hospitalisation, the number of days spent in hospital and proportion of children with extended stays (≥10 days).
METHODS
European population-based record-linkage study in 11 regions in eight countries including children with congenital anomalies (EUROCAT children) and without congenital anomalies (reference children) living in the same regions. The children were born between 1995 and 2014 and were followed to their tenth birthday or 31/12/2015. European meta-analyses of the outcome measures were performed by two age groups, <1 year and 1-4 years.
RESULTS
99,416 EUROCAT children and 2,021,772 reference children were linked to hospital databases. Among EUROCAT children, 85% (95%-CI: 79-90%) were hospitalised in the first year and 56% (95%-CI: 51-61%) at ages 1-4 years, compared to 31% (95%-CI: 26-37%) and 25% (95%-CI: 19-31%) of the reference children. Median length of stay was 2-3 times longer for EUROCAT children in both age groups. The percentages of children with extended stays (≥10 days) in the first year were 24% (95%-CI: 20-29%) for EUROCAT children and 1% (95%-CI: 1-2%) for reference children. The median length of stay varied greatly between congenital anomaly subgroups, with children with gastrointestinal anomalies and congenital heart defects having the longest stays.
CONCLUSIONS
Children with congenital anomalies were more frequently hospitalised and median length of stay was longer. The outlook improves after the first year. Parents of children with congenital anomalies should be informed about the increased hospitalisations required for their child's care and the impact on family life and siblings, and they should be adequately supported.

Identifiants

pubmed: 35867669
doi: 10.1371/journal.pone.0269874
pii: PONE-D-22-04212
pmc: PMC9307180
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0269874

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Lancet. 2010 Feb 20;375(9715):649-56
pubmed: 20092884
PLoS One. 2021 Aug 27;16(8):e0256535
pubmed: 34449798
Eur J Pediatr. 2017 Apr;176(4):435-441
pubmed: 28190103
BMJ Open. 2021 Jun 28;11(6):e047859
pubmed: 34183346
Res Synth Methods. 2010 Apr;1(2):97-111
pubmed: 26061376
Am J Med Genet A. 2014 Dec;164A(12):2979-86
pubmed: 25257471
J Am Heart Assoc. 2016 Jun 16;5(6):
pubmed: 27312802
Cureus. 2021 Feb 18;13(2):e13414
pubmed: 33758709
Biom J. 2020 Jan;62(1):69-98
pubmed: 31553488
BMC Pediatr. 2009 May 10;9:32
pubmed: 19426556
Arch Dis Child Fetal Neonatal Ed. 2018 Jan;103(1):F22-F28
pubmed: 28667189
Front Physiol. 2016 Mar 01;7:67
pubmed: 26973535
Kurume Med J. 2002;49(3):143-7
pubmed: 12471728
Control Clin Trials. 1986 Sep;7(3):177-88
pubmed: 3802833
J Am Heart Assoc. 2020 Aug 4;9(15):e016581
pubmed: 32691679
Int J Cardiol. 2017 Aug 15;241:149-155
pubmed: 28390741
PLoS Med. 2020 Sep 28;17(9):e1003356
pubmed: 32986711
J Pediatr Urol. 2018 Dec;14(6):552.e1-552.e7
pubmed: 30072120
Eur J Med Genet. 2018 Sep;61(9):513-517
pubmed: 29597096
PLoS One. 2013 Aug 13;8(8):e70401
pubmed: 23967074
Birth Defects Res A Clin Mol Teratol. 2011 Mar;91 Suppl 1:S2-15
pubmed: 21384531
Eur J Pediatr. 2021 Jul;180(7):2193-2198
pubmed: 33666724
Circ Cardiovasc Qual Outcomes. 2011 May;4(3):306-12
pubmed: 21505154
Pediatr Surg Int. 2019 Nov;35(11):1293-1300
pubmed: 31372730
Pediatr Cardiol. 2020 Jun;41(5):853-861
pubmed: 32162027

Auteurs

Stine Kjaer Urhoj (SK)

Department of Paediatrics and Adolescent Medicine, Lillebaelt Hospital, University Hospital of Southern Denmark, Kolding, Denmark.

Joachim Tan (J)

Population Health Research Institute, St George's, University of London, London, United Kingdom.

Joan K Morris (JK)

Population Health Research Institute, St George's, University of London, London, United Kingdom.

Joanne Given (J)

Faculty of Life and Health Sciences, Ulster University, Northern Ireland, United Kingdom.

Gianni Astolfi (G)

Dept. of Neuroscience and Rehabilitation, University of Ferrara, Ferrara, Italy.

Silvia Baldacci (S)

Unit of Epidemiology of Rare diseases and Congenital anomalies, Institute of Clinical Physiology, National Research Council, Pisa, Italy.

Ingeborg Barisic (I)

Children's Hospital Zagreb, Centre of Excellence for Reproductive and Regenerative Medicine, Medical School University of Zagreb, Zagreb, Croatia.

Joanna Brigden (J)

Population Health Research Institute, St George's, University of London, London, United Kingdom.

Clara Cavero-Carbonell (C)

Rare Diseases Research Unit, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (UVEG-FISABIO), Valencia, Spain.

Hannah Evans (H)

Population Health Research Institute, St George's, University of London, London, United Kingdom.

Mika Gissler (M)

Finnish Institute for Health and Welfare, Information Services Department, Helsinki, Finland.

Anna Heino (A)

Finnish Institute for Health and Welfare, Information Services Department, Helsinki, Finland.

Sue Jordan (S)

Faculty of Medicine, Health and Life Sciences, Swansea University, Wales, United Kingdom.

Renée Lutke (R)

Department of Genetics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

Ljubica Odak (L)

Children's Hospital Zagreb, Centre of Excellence for Reproductive and Regenerative Medicine, Medical School University of Zagreb, Zagreb, Croatia.

Aurora Puccini (A)

Territorial Assistance Service-Drug and Medical Device Area, Emilia Romagna Health Department, Bologna, Italy.

Michele Santoro (M)

Unit of Epidemiology of Rare diseases and Congenital anomalies, Institute of Clinical Physiology, National Research Council, Pisa, Italy.

Ieuan Scanlon (I)

Faculty of Medicine, Health and Life Sciences, Swansea University, Wales, United Kingdom.

Hermien E K de Walle (HEK)

Department of Genetics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

Diana Wellesley (D)

Clinical Genetics, Princess Anne Hospital, University of Southampton and Wessex Clinical Genetics Service, Southampton, United Kingdom.

Óscar Zurriaga (Ó)

Department of Preventive Medicine and Public Health, Rare Diseases Research Unit UVEG-FISABIO Valencia and Spanish Consortium for Biomedical Research in Epidemiology and Public Health, University of Valencia (Spain) and Valencia Region (Spain) Health Authority (Conselleria de Sanitat Universal I Salut Pública), Valencia, Spain.

Maria Loane (M)

Faculty of Life and Health Sciences, Ulster University, Northern Ireland, United Kingdom.

Ester Garne (E)

Department of Paediatrics and Adolescent Medicine, Lillebaelt Hospital, University Hospital of Southern Denmark, Kolding, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH